Taysha Update on TSHA-120 Program in Giant Axonal Neuropathy

 Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges with study design feasibility for potential Biologics License Application (BLA) submission

Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development

Strategic program prioritization will reduce operating expenses and is anticipated to extend cash runway into the fourth quarter of 2025 to support the continued development of TSHA-102 in evaluation for Rett syndrome

https://finance.yahoo.com/news/taysha-gene-therapies-provides-tsha-200100404.html